Careful consideration when responding to new data: dolutegravir and pregnancy
- PMID: 30050687
- PMCID: PMC6038127
- DOI: 10.1016/S2055-6640(20)30262-4
Careful consideration when responding to new data: dolutegravir and pregnancy
Abstract
This case highlights the current complexities of managing women in the early stages of pregnancy presenting on dolutegravir-based regimens. When responding to new data, there is an important decision to be made, between the potential, uncertain risk of teratogenicity against the potential increased risk of in utero vertical transmission of HIV-1.
Keywords: dolutegravir, pregnancy, treatment switch.
References
-
- World Health Organization Statement on DTG. Potential safety issue affecting women living with HIV using dolutegravir at the time of conception 18 May 2018. Available at: www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_201... ( accessed June2018).
-
- European Medicines Agency New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir. Press release 18 May 2018. Available at: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/05/... ( accessed June 2018).
Publication types
LinkOut - more resources
Full Text Sources